Short Sellers Pile Into Kuros Biosciences as Market Discounts a Profitable Turnaround

Kuros Biosciences fell 3.8% to a 52-week low of EUR 17.45 despite H1 2026 revenue up 45% and its first net profit of USD 4.4 million.

Kuros Biosciences closed Friday's session at EUR 17.56, down 3.8%, with the decline carrying the stock to a fresh 52-week low of EUR 17.45 intraday. The retreat extended a soft patch that has now stretched through the end of the trading week, and it came without any company-specific announcement or sector-wide trigger to explain it. Media reports during the day had hinted at a temporary rebound on the Swiss exchange, but sellers ultimately prevailed.

What separates this pullback from a routine bout of profit-taking is the activity building beneath the surface. Short interest in the medical device maker has been climbing steadily: reported short positions rose from 308,285 shares in mid-July to 337,280 by the end of that month, and reached 347,540 shares by August 14. That marks a 12.7% expansion in bearish bets over a single month — a signal that at least part of the market is positioning for further weakness rather than a rebound.

Valuation concerns have added to the pressure. Investors are debating whether the current price adequately reflects the company's prospects, and some worry that broader market dislocations could weigh on the shares regardless of how the business performs.

Fundamentals Tell a Different Story

The gap between the share price and the operating reality has rarely been wider. Roughly a month ago, Kuros reported first-half 2026 results showing revenue from its Medical Devices segment surged 45% year over year to USD 92.4 million, up from USD 63.5 million in the comparable prior-year period. Adjusted EBITDA advanced 61% to USD 12.5 million, a margin of 13.6%.

The bottom line delivered an even more significant milestone. Kuros posted a net profit of USD 4.4 million for the half, reversing a net loss of USD 2.0 million a year earlier. That swung the company into the black for the first time — a threshold reached roughly three weeks ago after a long stretch of heavy investment. Management also reaffirmed its full-year 2026 guidance about a month ago, targeting revenue growth of at least 35%, and has set its sights on EUR 300 million to EUR 330 million in revenue by 2028.

Analysts adjusted their earnings forecasts to reflect the new profitability about three weeks ago, and structural moves — including the appointment of a new Chief Operating Officer more than a month ago — were meant to reinforce the operating trajectory.

A Market That Isn't Buying It

None of it has been enough to restore investor confidence. The stock has failed to convert tangible business progress into sustained buying interest, leaving fundamentals and market valuation drifting apart. A durable floor has yet to form, and with short sellers still adding to their positions, the burden of proof remains on the company to show that its profitable turn is more than a single-half event.